ADARx Pharmaceuticals: Raises $46M in Series B-1 Financing

ADARx Pharmaceuticals Raises $46M in Series B-1 Financing

  • ADARx Pharmaceuticals, a San Diego, CA-based clinical stage biotechnology company developing RNA-targeting therapeutics, raised $46M in Series B-1 funding
  • The round was led by Ascenta Capital with participation from OrbiMed Advisors, SR One Capital Management, Lilly Asia Ventures, and Sirona Capital
  • In conjunction with this financing, Dr. Lorence Kim of Ascenta Capital has joined the Company’s Board of Directors
  • The company intends to use the funds to advance its proprietary RNA targeting platform
  • Led by CEO and President Dr. Zhen Li, ADARx is a clinical stage biotechnology company
  • The company is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Talos and Nasdaq Strengthen On-Chain and Off-Chain Collateral Workflow

New partnership enhances digital asset handling and collateral management.Highlights: Talos and Nasdaq collaborate to streamline collateral workflows.Partnership aims...

FCA Restricts Use of Sensitive Data in AI Trial with Palantir

Regulatory concerns arise over data handling protocols in AI trials.Highlights: FCA criticized for using sensitive data in AI...

Bank of Ireland Strengthens AI Readiness for Staff Training

New initiatives prepare employees for an AI-driven banking landscape.Highlights: Bank of Ireland launches AI training initiatives for staff.Employees...

MAS Develops AI Risk Management Toolkit to Strengthen Financial Sector

New toolkit aims to enhance risk management within Singapore's finance industry.Highlights: MAS launches an AI Risk Management Toolkit...